Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoSand HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.